IDEMIA
19.7.2021 11:28:07 CEST | Business Wire | Press release
IDEMIA Group announced today the appointment of Dominique Cerutti as Group Board Member, effective July 1st 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210719005297/en/
Dominique Cerutti comes with over 35 years of experience in Technology, R&D and Engineering services. He has held several CEO positions of leading technology companies and his expertise in growing large-scale international businesses will be a significant contribution to IDEMIA’s strategic vision.
“Dominique is a very seasoned leader with a demonstrated track record in transforming and growing large-scale international technology businesses. He will be instrumental for the Group moving forward”, said Pierre Barrial, IDEMIA Group President & CEO.
“We are pleased to welcome Dominique Cerutti to the IDEMIA Board. With more than 35 years of experience, Dominique is an undisputed expert in security and technology and a tremendous addition to IDEMIA’s Board” said Yann Delabrière, Chairman of the Board
“I couldn’t be more honored and thrilled to be joining IDEMIA, global leader in Augmented Identity, at an exciting time in its development. I look forward to offering strategic guidance and contributing to making the world a safer place”, said Dominique Cerutti.
NOTE TO EDITORS – Dominique Cerutti’s biography
Starting June 2015, Dominique Cerutti spent 5 years as Chief Executive Officer of the Altran group. He was also Chairman of the Altran Board from June 2015 to April 2020, until the acquisition of the company by Capgemini. Under his leadership, Altran has become the undisputed global leader in Engineering and R&D services, growing from 20,000 to more than 50,000 engineers worldwide, with revenues up to 3.2bn euros. He has deeply transformed the company by adapting the organization, promoting new business models and driving major acquisitions, enabling Altran to stay ahead of the competition, drive the market and reshape the global ER&D industry. Fervent advocate of the acquisition by Capgemini, he has worked hand in hand with the Group to make the integration a success and stepped down at the end of 2020.
Before joining Altran, Dominique Cerutti was CEO and Chairman of the Managing Board of Euronext, the leading pan-European exchange. He established Euronext as an independent company and the leading pan-European Exchange, through a successful IPO following the acquisition of NYSE-Euronext by the ICE Group in November 2013 and the subsequent demerger of Euronext from NYSE. He led the strategic repositioning of Euronext as the premier pan-European financing center. He and his team have been deeply involved with the correction of the previously biased EU financial markets regulation, promoting transparency and increased investors protections within the EU financial markets.
He was previously President and Deputy CEO, and a board member of New-York Stock Exchange (NYSE), the world’s leading exchange Group.
Dominique Cerutti also spent over 20 years at IBM in an international career, where he contributed to the company’s strategic transformation. In particular, he served as Chief Executive Officer of IBM Global Services for the Europe, Middle East, Africa, and later for IBM Europe, after being Executive Assistant to Lou Gerstner, Chairman and CEO of IBM.
He held various Board positions at LCH-Clearnet, Euromed Business School, New-York Stock Exchange, Altran, Euronext, Genes’ink.
Since March 2021, he is chairman of Adarma’s Board, one of the largest independent security services companies in the UK.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
